Driehaus Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Driehaus Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-96,424	Closed	-$30.5M	–	463
2023 Q4	$30.5M	Buy	96,424 +5,745	+6%	+$1.12M	0.37%	75
2023 Q3	$15.3M	Buy	90,679 +229	+0.3%	+$43.1K	0.2%	160
2023 Q2	$19.6M	Buy	90,450 +3,028	+3%	+$649K	0.25%	136
2023 Q1	$15.9M	Buy	87,422 +2,072	+2%	+$396K	0.22%	148
2022 Q4	$16.8M	Buy	85,350 +1,885	+2%	+$404K	0.25%	137
2022 Q3	$18.8M	Buy	+83,465	New	+$16.9M	0.28%	109

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Driehaus Capital Management's KRTX Position: Q1 2024 in Review

Driehaus Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 96,424 shares — an estimated $30.5M sold.

Driehaus Capital Management first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $30.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Driehaus Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Driehaus Capital Management sold 96,424 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $30.5M.
Driehaus Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
Driehaus Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $30.5M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Driehaus Capital Management's 13F filing for Q1 2024, filed 15 May 2024.